Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Pimicotinib |
| Synonyms | |
| Therapy Description |
Pimjetmi (pimicotinib) selectively inhibits CSF1R, potentially leading to inhibition of tumor cell proliferation, enhanced T cell immune response, and antitumor activity (J Clin Oncol 41, 2023 (suppl 16; abstr 11559, PMID: 41796601). Pimjetmi (pimicotinib) is FDA-approved for use in patients with symptomatic tenosynovial giant cell tumor (FDA.gov). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Pimicotinib | Pimjetmi | ABSK 021|ABSK-021|CSF-1R Inhibitor ABSK021|ABSK021 | CSF1R Inhibitor 28 | Pimjetmi (pimicotinib) selectively inhibits CSF1R, potentially leading to inhibition of tumor cell proliferation, enhanced T cell immune response, and antitumor activity (J Clin Oncol 41, 2023 (suppl 16; abstr 11559, PMID: 41796601). Pimjetmi (pimicotinib) is FDA-approved for use in patients with symptomatic tenosynovial giant cell tumor (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05804045 | Phase III | Pimicotinib | Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor | Active, not recruiting | USA | POL | NLD | ITA | ESP | CAN | 1 |
| NCT07499362 | Phase II | Pimicotinib | Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) | Recruiting | 1 | |
| NCT04192344 | Phase I | Pimicotinib | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK021 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |